Richard Barohn
Neuromuscular Medicine · Columbia, MONPI 1073610663
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $9,564 of the $10,567 with a category attached, or 90.5%. UCB SA accounts for 85.2% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2021 at $9,133 and has fallen 89.4% since, to $966 in 2024.
Across 11 payments — averaging $960.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB SA$9K
- Sanofi$750
- Sanofi US Services Inc.$379
- Argenx US, Inc.$185
- Siemens Medical Solutions USA, Inc.$114
- UCB, Inc.$71
- plus $68 from 2 others
Across 57 payments — averaging $6279.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$284K
- Sanofi$41K
- AstraZeneca$25K
- Sarepta Therapeutics, Inc.$7K
- Argenx US, Inc.$853
- Regeneron$377
- plus $360 from 1 others
What the payments were for
- Consulting fees$9,56491%
- Speaking & faculty fees$7507%
- Food & beverage$2532%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB SA | 1 | $9,000 |
| Sanofi | 2 | $750 |
| Sanofi US Services Inc. | 1 | $379 |
| Argenx US, Inc. | 1 | $185 |
| Siemens Medical Solutions USA, Inc. | 2 | $114 |
| UCB, Inc. | 1 | $71 |
| AbbVie(2 entities) | 2 | $37 |
| Amneal Pharmaceuticals LLC | 1 | $31 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEXVIAZYME$750
- VYVGART$185
How this compares
Too few neuromuscular medicine providers in Missourito place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Radicava OrsEdaravone | 13 | $181,644 |
Paid to pharmacies, not to this prescriber.
Other neuromuscular medicine in Columbia
- William ArnoldColumbia$42K
- Ryan CastoroColumbia$7K
- Erik EnsrudColumbia$5K
- Karim SalameColumbia$4K
- Nesreen JaafarColumbia$255
- Melanie GlennColumbia$90
- Niranjan SinghSaint Louis$60K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.